Medtronic pays Abbott $400m to end all stent litigation
This article was originally published in Clinica
Executive Summary
Medtronic and Abbott Laboratories’ rivalry in the coronary stent market will remain out of court for the foreseeable future after the two firms resolved all outstanding intellectual property litigation.